Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Group 1: Moderna's Earnings Outlook - Moderna is expected to report a year-over-year decline in earnings, with a projected loss of $2.65 per share, reflecting a change of -581.8% [3][12] - Revenues for the upcoming quarter are anticipated to be $955.23 million, down 66% from the same quarter last year [3] - The earnings report is scheduled for release on February 14, 2025, and could influence stock movement based on whether results exceed or fall short of expectations [2][12] Group 2: Earnings Estimate Revisions - The consensus EPS estimate for Moderna has been revised 7.2% higher in the last 30 days, indicating a more optimistic outlook from analysts [4] - The Most Accurate Estimate for Moderna is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +3.26%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Group 3: Historical Performance and Predictive Indicators - Moderna has a history of beating consensus EPS estimates, having done so in the last four quarters [13] - The predictive power of the Earnings ESP is significant for positive readings, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - Despite a positive earnings outlook, other factors may also influence stock performance, making it essential to consider broader market conditions [14][16] Group 4: Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals is expected to post a loss of $0.21 per share, indicating a year-over-year change of +80.9% [17] - Alnylam's revenue is projected to be $570.11 million, up 29.7% from the previous year, but it has an Earnings ESP of -192.68%, complicating predictions for beating the consensus EPS estimate [18]